Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APLS Apellis Pharmaceuticals	$27.35 -2.2%	$20.96	$16.10 ▼ $41.94	$3.45B	0.78	2.30 million shs	578,235 shs
HCM HUTCHMED	$15.91 -1.3%	$16.42	$11.51 ▼ $21.50	$2.78B	0.55	81,431 shs	36,009 shs
IMTX Immatics	$5.26 -7.6%	$6.00	$3.30 ▼ $13.09	$644.22M	0.93	759,424 shs	723,422 shs
INDV Indivior	$24.01 -1.3%	$17.81	$7.33 ▼ $24.66	N/A	0.74	1.81 million shs	910,332 shs

These 7 Stocks Will Be Magnificent in 2025

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APLS Apellis Pharmaceuticals	0.00%	+0.79%	+42.78%	+60.38%	-30.27%
HCM HUTCHMED	0.00%	-2.13%	-8.57%	+20.15%	-6.72%
IMTX Immatics	0.00%	-10.11%	-13.26%	+11.35%	-49.24%
INDV Indivior	0.00%	+3.67%	+41.89%	+115.99%	+97.72%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
APLS Apellis Pharmaceuticals	4.2328 of 5 stars	3.3	1.0	4.4	4.1	2.5	0.6
HCM HUTCHMED	2.4748 of 5 stars	3.5	2.0	0.0	1.7	0.0	1.9
IMTX Immatics	1.8838 of 5 stars	3.4	3.0	0.0	1.1	1.7	0.0
INDV Indivior	1.6847 of 5 stars	1.6	4.0	0.0	1.1	1.7	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
APLS Apellis Pharmaceuticals	2.58	Moderate Buy	$34.12	24.73% Upside
HCM HUTCHMED	3.00	Buy	$28.00	76.05% Upside
IMTX Immatics	2.83	Moderate Buy	$14.67	179.05% Upside
INDV Indivior	3.17	Buy	$19.60	-18.35% Downside

Current Analyst Ratings Breakdown

Latest IMTX, HCM, INDV, and APLS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/15/2025	IMTX Immatics	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
8/11/2025	HCM HUTCHMED	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
8/6/2025	INDV Indivior	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$27.00
8/4/2025	APLS Apellis Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$35.00 ➝ $37.00
8/1/2025	APLS Apellis Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Perform ➝ Sector Perform	$17.00 ➝ $19.00
8/1/2025	APLS Apellis Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$39.00 ➝ $40.00
8/1/2025	APLS Apellis Pharmaceuticals	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$52.00 ➝ $50.00
7/29/2025	APLS Apellis Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$41.00 ➝ $46.00
7/22/2025	HCM HUTCHMED	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$27.00 ➝ $28.00
7/22/2025	INDV Indivior	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$20.00
7/18/2025	APLS Apellis Pharmaceuticals	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$47.00 ➝ $50.00

(Data available from 8/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
APLS Apellis Pharmaceuticals	$754.65M	4.58	N/A	N/A	$1.84 per share	14.87
HCM HUTCHMED	$602.20M	4.61	$0.28 per share	56.07	$4.43 per share	3.59
IMTX Immatics	$168.65M	3.79	$0.23 per share	23.29	$5.12 per share	1.03
INDV Indivior	$1.19B	N/A	$1.80 per share	13.36	($2.52) per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
APLS Apellis Pharmaceuticals	-$197.88M	-$1.82	N/A	N/A	N/A	-30.24%	-116.09%	-26.72%	11/4/2025 (Estimated)
HCM HUTCHMED	$37.73M	N/A	0.00	10.89	N/A	N/A	N/A	N/A	N/A
IMTX Immatics	$16.47M	-$0.65	N/A	N/A	N/A	-59.29%	-15.60%	-12.31%	N/A
INDV Indivior	$2M	$0.62	38.72	14.04	N/A	6.65%	-86.28%	16.26%	10/23/2025 (Estimated)

Latest IMTX, HCM, INDV, and APLS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q1 2025	IMTX Immatics	-$0.38	-$0.66	-$0.28	-$0.66	$13.05 million	$6.48 million
7/31/2025	Q2 2025	APLS Apellis Pharmaceuticals	-$0.44	-$0.33	+$0.11	-$0.33	$187.91 million	$171.39 million
7/31/2025	Q2 2025	INDV Indivior	$0.26	$0.51	+$0.25	$0.14	$239.43 million	$302.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
APLS Apellis Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
HCM HUTCHMED	N/A	N/A	N/A	N/A	N/A
IMTX Immatics	N/A	N/A	N/A	N/A	N/A
INDV Indivior	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
APLS Apellis Pharmaceuticals	2.90	3.77	3.16
HCM HUTCHMED	0.05	4.65	4.51
IMTX Immatics	N/A	8.80	8.80
INDV Indivior	N/A	0.90	0.76

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
APLS Apellis Pharmaceuticals	96.29%
HCM HUTCHMED	8.82%
IMTX Immatics	64.41%
INDV Indivior	60.33%

Insider Ownership

Company	Insider Ownership
APLS Apellis Pharmaceuticals	6.50%
HCM HUTCHMED	3.60%
IMTX Immatics	N/A
INDV Indivior	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
APLS Apellis Pharmaceuticals	770	126.29 million	117.70 million	Optionable
HCM HUTCHMED	1,811	174.42 million	168.14 million	Not Optionable
IMTX Immatics	260	121.55 million	N/A	Optionable
INDV Indivior	1,051	N/A	N/A	Not Optionable

IMTX, HCM, INDV, and APLS Headlines

Recent News About These Companies

Indivior Updates CFO Employment Agreements

August 22 at 8:35 PM | msn.com

Indivior to Participate in Upcoming Investor Events

August 20, 2025 | prnewswire.com

Brokerages Set Indivior PLC (NASDAQ:INDV) Price Target at $19.60

August 19, 2025 | americanbankingnews.com

Indivior (NASDAQ:INDV) Hits New 52-Week High - Time to Buy?

August 12, 2025 | marketbeat.com

Equities Analysts Set Expectations for Indivior Q3 Earnings

August 9, 2025 | marketbeat.com

XTX Topco Ltd Has $481,000 Holdings in Indivior PLC (NASDAQ:INDV)

August 9, 2025 | marketbeat.com

The Street Loves This ‘Strong Buy’ Pharma Stock

August 8, 2025 | finance.yahoo.com

Indivior Raises 2025 Guidance After Strong Q2 Results

August 6, 2025 | theglobeandmail.com

Indivior initiated with a Buy at H.C. Wainwright

August 6, 2025 | msn.com

Indivior (INDV) Q2 EPS Jumps 104%

August 6, 2025 | theglobeandmail.com

HC Wainwright & Co. Initiates Coverage of Indivior (INDV) with Buy Recommendation

August 6, 2025 | msn.com

Cannabis Stocks To Follow Now - August 5th

August 6, 2025 | marketbeat.com

Indivior (NASDAQ:INDV) Reaches New 52-Week High - Here's Why

August 5, 2025 | marketbeat.com

All You Need to Know About Indivior (INDV) Rating Upgrade to Strong Buy

August 5, 2025 | zacks.com

Best Momentum Stock to Buy for August 5th

August 5, 2025 | zacks.com

New Strong Buy Stocks for August 5th

August 5, 2025 | zacks.com

Cannabis Stocks To Keep An Eye On - August 2nd

August 3, 2025 | marketbeat.com

Kazazian Asset Management LLC Has $757,000 Stock Holdings in Indivior PLC (NASDAQ:INDV)

August 3, 2025 | marketbeat.com

Indivior (INDV) Extends Jump on 3rd Day with 16% Gain

August 1, 2025 | finance.yahoo.com

Indivior PLC 2025 Q2 - Results - Earnings Call Presentation

August 1, 2025 | seekingalpha.com

10 Stocks Crushing With Whopping Double-Digit Gains

July 31, 2025 | insidermonkey.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMTX, HCM, INDV, and APLS Company Descriptions

Apellis Pharmaceuticals NASDAQ:APLS

$27.35 -0.62 (-2.21%)

As of 03:46 PM Eastern

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.

HUTCHMED NASDAQ:HCM

$15.90 -0.21 (-1.27%)

As of 03:45 PM Eastern

HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The Other Ventures segment involves the other commercial businesses which include the sales, marketing, manufacture, and distribution of prescription drugs and healthcare products. The company was founded on December 18, 2000 and is headquartered in Hong Kong.

Immatics NASDAQ:IMTX

$5.26 -0.43 (-7.63%)

As of 03:46 PM Eastern

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.

Indivior NASDAQ:INDV

$24.00 -0.32 (-1.30%)

As of 03:45 PM Eastern

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time